.jpeg)
The marketing status of Pomalidomide
Pomalidomide (Pomalidomide), sold under the trade names Pomalyst and Imnovid, is an anticancer drug used to treat multiple myeloma and AIDS-related Kaposi's sarcoma. Pomalidomide was approved for medical use by the U.S. Food and Drug Administration (FDA) in February 2013 and the European Medicines Agency (EMA) in August of the same year. Multiple myeloma is rare, and pomalidomide was designated an "orphan drug" (a drug for rare diseases) in 2009. Pomalidomide, independently developed in China, has been launched in China and is currently covered by medical insurance.
[ 免责声明 ] 本页面内容来自公开渠道（如FDA官网、Drugs官网、原研药厂官网等），仅供持有医疗专业资质的人员用于医学药学研究参考，不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市，不适用于中国境内销售和使用。如需治疗，请咨询正规医疗机构。本站不提供药品销售或代购服务。
